The House of Representatives last night voted 234-183 to pass legislation (H.R. 987) that combines several AHA-supported bills to help lower prescription drug costs and strengthen the Affordable Care Act’s health insurance marketplaces. The legislation’s drug-related provisions would allow generic drug manufacturers facing certain anticompetitive delay tactics to bring an action in federal court for injunctive relief, and help decrease the time it takes for generic competitors to get to market. The ACA marketplace provisions would provide funding to expand navigator support and outreach to help consumers enroll in individual market coverage, and void a final rule that expanded short-term limited duration health plans. 
 

Related News Articles

Headline
Instead of attacking hospitals and health systems caring for patients during the COVID-19 pandemic, PhRMA should instead focus on lowering the costs of drugs…
Blog
America’s hospitals and health systems, and our heroic caregivers, have been on the front lines of the battle against COVID-19 for the past year, working…
Headline
The Supreme Court should hold the Affordable Care Act’s individual mandate constitutional, the Department of Justice said in a letter today to the Supreme…
Headline
AHA today urged the Centers for Medicare & Medicaid Services to immediately withdraw its Most Favored Nation model interim final rule and “replace it with…
Headline
The AHA yesterday filed a declaration supporting other organizations seeking a temporary restraining order and preliminary injunction to prevent the Centers…
Headline
The Trump administration today announced two actions that it claims will lower prescription drug prices. The Most Favored Nation Model would cut payments to…